Pesquisa | BVS Doenças Infecciosas e Parasitárias

1.

Examining crossover and postprotocol therapies in first-line immunotherapy trials in non-small cell lung cancer (NSCLC).

Desai, Aakash; Smith, Caleb J; Pritchett, Joshua C; Leventakos, Konstantinos; West, Howard Jack.

Cancer ; 2024 Feb 14.

Artigo em Inglês | MEDLINE | ID: mdl-38353476

2.

ChatGPT-A promising generative AI tool and its implications for cancer care.

Uprety, Dipesh; Zhu, Dongxiao; West, Howard Jack.

Cancer ; 129(15): 2284-2289, 2023 08 01.

Artigo em Inglês | MEDLINE | ID: mdl-37183438

3.

Clinical and economic impact of recurrence in early-stage non-small-cell lung cancer following complete resection.

West, Howard; Hu, Xiaohan; Chirovsky, Diana; Walker, Mark S; Wang, Yuexi; Kaushiva, Alpana; Tepsick, Jon; Samkari, Ayman.

Future Oncol ; 19(20): 1415-1427, 2023 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-37218514

4.

Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0?

West, Howard Jack; Barzi, Afsaneh; Wong, Debra.

Curr Oncol Rep ; 24(12): 1843-1850, 2022 12.

Artigo em Inglês | MEDLINE | ID: mdl-36208400

5.

Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.

Weiss, Jared M; Pennell, Nathan; Deal, Allison M; Morgensztern, Daniel; Bradford, Daniel S; Crane, Jeffrey; West, Howard Jack; Lee, Carrie; Pecot, Chad; Stevenson, James P; Irvin, William; Socinski, Mark; Stinchcombe, Tom; Villaruz, Liza C; Muss, Hyman B.

Cancer ; 126(5): 1060-1067, 2020 03 01.

Artigo em Inglês | MEDLINE | ID: mdl-31943168

6.

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.

West, Howard; McCleod, Michael; Hussein, Maen; Morabito, Alessandro; Rittmeyer, Achim; Conter, Henry J; Kopp, Hans-Georg; Daniel, Davey; McCune, Steven; Mekhail, Tarek; Zer, Alona; Reinmuth, Niels; Sadiq, Ahad; Sandler, Alan; Lin, Wei; Ochi Lohmann, Tania; Archer, Venice; Wang, Lijia; Kowanetz, Marcin; Cappuzzo, Federico.

Lancet Oncol ; 20(7): 924-937, 2019 07.

Artigo em Inglês | MEDLINE | ID: mdl-31122901

7.

Lessons from ADAURA: Can we improve on a positive trial?

West, Howard Jack; Pennell, Nathan A.

Cancer ; 130(5): 659-664, 2024 03 01.

Artigo em Inglês | MEDLINE | ID: mdl-37962066

8.

ABIM Maintenance of Certification-Reply.

Uprety, Dipesh; West, Howard Jack.

JAMA ; 331(3): 261-262, 2024 01 16.

Artigo em Inglês | MEDLINE | ID: mdl-38113138

9.

Maintenance of Certification (MOC)-Benefit vs Burden.

Uprety, Dipesh; West, Howard Jack.

JAMA ; 330(14): 1329-1330, 2023 10 10.

Artigo em Inglês | MEDLINE | ID: mdl-37738250

10.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Shaw, Alice T; Gandhi, Leena; Gadgeel, Shirish; Riely, Gregory J; Cetnar, Jeremy; West, Howard; Camidge, D Ross; Socinski, Mark A; Chiappori, Alberto; Mekhail, Tarek; Chao, Bo H; Borghaei, Hossein; Gold, Kathryn A; Zeaiter, Ali; Bordogna, Walter; Balas, Bogdana; Puig, Oscar; Henschel, Volkmar; Ou, Sai-Hong Ignatius.

Lancet Oncol ; 17(2): 234-242, 2016 Feb.

Artigo em Inglês | MEDLINE | ID: mdl-26708155

11.

Chemoimmunotherapy for stage IV non-small-cell lung cancer - Authors' reply.

Cappuzzo, Federico; West, Howard.

Lancet Oncol ; 20(9): e467, 2019 09.

Artigo em Inglês | MEDLINE | ID: mdl-31486366

12.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Gadgeel, Shirish M; Gandhi, Leena; Riely, Gregory J; Chiappori, Alberto A; West, Howard L; Azada, Michele C; Morcos, Peter N; Lee, Ruey-Min; Garcia, Linta; Yu, Li; Boisserie, Frederic; Di Laurenzio, Laura; Golding, Sophie; Sato, Jotaro; Yokoyama, Shumpei; Tanaka, Tomohiro; Ou, Sai-Hong Ignatius.

Lancet Oncol ; 15(10): 1119-28, 2014 Sep.

Artigo em Inglês | MEDLINE | ID: mdl-25153538

13.

Managing multifocal bronchioloalveolar carcinoma/lepidic predominant adenocarcinoma: changing rules for an evolving clinical entity.

West, Howard Jack.

Clin Adv Hematol Oncol ; 12(9): 593-600, 2014 Sep.

Artigo em Inglês | MEDLINE | ID: mdl-25654480

14.

Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.

West, Howard Jack; Kim, Jae Y.

JAMA Oncol ; 10(2): 249-255, 2024 Feb 01.

Artigo em Inglês | MEDLINE | ID: mdl-38153722

15.

Brief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer.

Sridhar, Arthi; West, Howard Jack; Singhi, Eric K.

Clin Lung Cancer ; 2024 Apr 30.

Artigo em Inglês | MEDLINE | ID: mdl-38772808

16.

Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting.

Gadgeel, Shirish M; Rai, Pragya; Annavarapu, Srinivas; Alam, Sartaj; Goldschmidt, Jerome H; West, Howard Jack; Santorelli, Melissa; Martins, Renata Eiras.

Front Oncol ; 14: 1298603, 2024.

Artigo em Inglês | MEDLINE | ID: mdl-38525422

17.

Perioperative Therapy for Resectable Non-Small-Cell Lung Cancer: Weighing Options for the Present and Future.

Uprety, Dipesh; West, Howard Jack.

JCO Oncol Pract ; 19(7): 403-409, 2023 07.

Artigo em Inglês | MEDLINE | ID: mdl-37023371

18.

Perioperative Immune Checkpoint Inhibition in Early-Stage Non-Small Cell Lung Cancer: A Review.

Desai, Aakash P; Adashek, Jacob J; Reuss, Joshua E; West, Howard Jack; Mansfield, Aaron S.

JAMA Oncol ; 9(1): 135-142, 2023 01 01.

Artigo em Inglês | MEDLINE | ID: mdl-36394834

19.

The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer.

Tam, Andrew; Eustace, Nicholas; Kassardjian, Ari; West, Howard; Williams, Terence M; Amini, Arya.

Surg Oncol Clin N Am ; 32(3): 497-514, 2023 07.

Artigo em Inglês | MEDLINE | ID: mdl-37182989

20.

Challenges in synergizing radiotherapy with immunotherapy to unlock the abscopal effect in metastatic NSCLC: A systematic review.

Liu, Jason; West, Howard; McGee, Heather M; Williams, Terence M; Lee, Percy; Amini, Arya.

Neoplasia ; 43: 100914, 2023 09.

Artigo em Inglês | MEDLINE | ID: mdl-37348427

BVS Doenças Infecciosas e Parasitárias

Informação e Conhecimento para a Saúde

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar:

Examining crossover and postprotocol therapies in first-line immunotherapy trials in non-small cell lung cancer (NSCLC).

ChatGPT-A promising generative AI tool and its implications for cancer care.

Clinical and economic impact of recurrence in early-stage non-small-cell lung cancer following complete resection.

Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0?

Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.

Lessons from ADAURA: Can we improve on a positive trial?

ABIM Maintenance of Certification-Reply.

Maintenance of Certification (MOC)-Benefit vs Burden.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Chemoimmunotherapy for stage IV non-small-cell lung cancer - Authors' reply.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Managing multifocal bronchioloalveolar carcinoma/lepidic predominant adenocarcinoma: changing rules for an evolving clinical entity.

Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.

Brief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer.

Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting.

Perioperative Therapy for Resectable Non-Small-Cell Lung Cancer: Weighing Options for the Present and Future.

Perioperative Immune Checkpoint Inhibition in Early-Stage Non-Small Cell Lung Cancer: A Review.

The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer.

Challenges in synergizing radiotherapy with immunotherapy to unlock the abscopal effect in metastatic NSCLC: A systematic review.